A recent clinical trial examining the effect of Nexavar (sorafenib) on multiple myeloma patients was terminated because of lack of effectiveness.

Nexavar is currently approved for the treatment of advanced kidney and liver cancers. It acts to stop the activity of overactive proteins that can cause cells to become cancerous.

This Phase 2 study enrolled 23 heavily pretreated multiple myeloma patients, who were given a 400 mg oral dose of Nexavar daily until their disease progressed or toxicity was noted.

The study was terminated because of lack of effectiveness or severe toxicity…